Free Trial
NYSEAMERICAN:YCBD

cbdMD Q3 2024 Earnings Report

cbdMD logo
$0.67 -0.02 (-2.32%)
Closing price 04:10 PM Eastern
Extended Trading
$0.67 +0.00 (+0.60%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

cbdMD EPS Results

Actual EPS
-$1.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

cbdMD Revenue Results

Actual Revenue
$5.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

cbdMD Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
4:10PM ET

Upcoming Earnings

cbdMD's Q3 2026 earnings is estimated for Wednesday, August 19, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

cbdMD Earnings Headlines

Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
cbdMD (YCBD) Stock Forecast & Price Target
See More cbdMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like cbdMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on cbdMD and other key companies, straight to your email.

About cbdMD

cbdMD (NYSEAMERICAN:YCBD) (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.

The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities. Third-party laboratory testing is conducted on every batch to verify potency and ensure products are free of THC or within federally approved limits. cbdMD markets both broad-spectrum and isolate-based formulations, targeting consumers seeking natural alternatives for stress relief, sleep support, and post-exercise recovery.

cbdMD’s distribution network spans e-commerce, major online marketplaces, and brick-and-mortar retailers across the United States, with expanding presence in select international markets. The company partners with pharmacies, specialty wellness stores, and veterinarians to broaden its retail footprint, while its direct-to-consumer website serves as a primary channel for product innovation feedback and subscription services.

Since its listing on the NYSE American exchange, cbdMD has pursued strategic product line extensions and marketing collaborations to drive brand awareness. The company emphasizes quality assurance, regulatory compliance, and ongoing research to support the evolving cannabinoid market and to meet consumer demand for trusted CBD solutions.

View cbdMD Profile